Partial growth-hormone insensitivity: the role of growth-hormone receptor mutations in idiopathic short stature.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this phase 2 clinical trial publication.

Mutations in the GHR locus may play a role in the cause of idiopathic short stature (ISS) by impairing growth-hormone (GH) receptor (GHR) function.

At one extreme, mutations that nullify the function of the GH receptor are linked to complete GH insensitivity syndrome, or Laron syndrome, and the researchers hypothesized that less-disruptive mutations could contribute to partial GH insensitivity syndrome.

Who Took Part

According to the abstract, 14 children were involved.

By PubMed's age tags, the people studied were young children and children, both men and women.

What Was Measured

Low levels of GH binding protein may indicate mutations in the extracellular domain of the receptor, and by focusing on 14 children with ISS who had low GH binding protein and insulin-like growth factor I levels, the researchers found three heterozygotes and one compound heterozygote for mutations in the extracellular domain of the receptor.

The subject headings attached to it are Body Height, Carrier Proteins, Chromosome Mapping, Gene Expression Regulation, Genes, Growth Disorders and Growth Hormone.

What This Means in Plain Language

This is a phase 2 clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 14 children.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1997 (The Journal of pediatrics), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.